Abstract
Background and aims: Almost 30% of strokes are recurrent events that are more likely to result in disability or death. This review aims to assess the efficacy of statin treatment for stroke recurrence in patients with ischaemic stroke.
Methods: Four electronic databases were searched to identify published Randomised Controlled Trials (RCTs) and observational cohort studies following PRISMA guidelines. The primary outcome of this study was a recurrent stroke of any type, and the secondary outcome was divided into recurrent ischaemic stroke and recurrent haemorrhagic stroke. Odds ratio (OR) was used to assess the effect of statin therapy. Meta-analysis was conducted under RevMan 5.4 software.
Results: The initial searches identified 559 papers, of which 11 randomised controlled trials and 12 observational cohort studies were included. For primary outcome, 11 RCTs (odds ratio 0.87, 95% CI [0.77,0.97]; P=0.02) and 12 cohort studies (odds ratio 0.80; 95% CI [0.66, 0.96]; P=0.02) showed similar results that statin therapy exerted beneficial impact on preventing recurrent stroke of any type in ischaemic stroke survivors. For secondary outcome, analysis of 6 RCTs (odds ratio 0.81; 95% CI [0.70, 0.93]; P=0.002) and 3 observational studies (odds ratio 0.67; 95% CI [0.61, 0.75]; P<0.00001) both displayed that statin therapy exerted positive impact on secondary prevention of ischaemic stroke.
Conclusions: Statin therapy has a positive effect on reducing the risk of recurrent stroke (any type) and recurrent ischaemic stroke for ischaemic stroke survivors; however, no strong evidence can prove statin reduces the risk of recurrent haemorrhagic stroke.
Methods: Four electronic databases were searched to identify published Randomised Controlled Trials (RCTs) and observational cohort studies following PRISMA guidelines. The primary outcome of this study was a recurrent stroke of any type, and the secondary outcome was divided into recurrent ischaemic stroke and recurrent haemorrhagic stroke. Odds ratio (OR) was used to assess the effect of statin therapy. Meta-analysis was conducted under RevMan 5.4 software.
Results: The initial searches identified 559 papers, of which 11 randomised controlled trials and 12 observational cohort studies were included. For primary outcome, 11 RCTs (odds ratio 0.87, 95% CI [0.77,0.97]; P=0.02) and 12 cohort studies (odds ratio 0.80; 95% CI [0.66, 0.96]; P=0.02) showed similar results that statin therapy exerted beneficial impact on preventing recurrent stroke of any type in ischaemic stroke survivors. For secondary outcome, analysis of 6 RCTs (odds ratio 0.81; 95% CI [0.70, 0.93]; P=0.002) and 3 observational studies (odds ratio 0.67; 95% CI [0.61, 0.75]; P<0.00001) both displayed that statin therapy exerted positive impact on secondary prevention of ischaemic stroke.
Conclusions: Statin therapy has a positive effect on reducing the risk of recurrent stroke (any type) and recurrent ischaemic stroke for ischaemic stroke survivors; however, no strong evidence can prove statin reduces the risk of recurrent haemorrhagic stroke.
Original language | English |
---|---|
Article number | P0319/403 |
Pages (from-to) | 244-244 |
Journal | European Stroke Journal |
Volume | 7 |
Issue number | 1_suppl |
DOIs | |
Publication status | Published - 3 May 2022 |